STAT3 antisense oligonucleotide AZD9150 in a subset of patients with heavily pretreated lymphoma: results of a phase 1b trialMatthew J. Reilley, David S. Hong, Carl Cook et al.|Journal for ImmunoTherapy of Cancer|2018Cited by 286
<i>STAT3</i> Antisense Oligonucleotide Remodels the Suppressive Tumor Microenvironment to Enhance Immune Activation in Combination with Anti–PD-L1Theresa A. Proia, Patricia McCoon|Clinical Cancer Research|2020Cited by 52